Dirloctogene samoparvovec, also known as SPK-8011, is an experimental gene therapy developed for hemophilia A by Roche and Spark Therapeutics.
[1][2][3][4][5][6] It uses an engineered AAV vector to cause liver cells to produce the Factor VIII blood clotting protein.
[3]